Published 2 months ago

Gilead's Aggressive Push Beyond HIV Treatments - Plans To Increase Cancer-Focused CAR-T Treatment Production - Gilead Sciences (NASDAQ:GILD)

Summary by Ground News

Gilead Sciences Inc. plans to increase its production of cell therapy cancer treatments fourfold by 2026. The company acquired Kite cell therapy in 2017 for nearly $12 billion. Gilead anticipates that oncology products will constitute a third of its revenue by the decade's end.

0 Articles

All

Left

Center

Right

Benzinga

Gilead's Aggressive Push Beyond HIV Treatments - Plans To Increase Cancer-Focused CAR-T Treatment Production - Gilead Sciences (NASDAQ:GILD)

Gilead Sciences plans to quadruple cell therapy cancer treatment production by 2026. With a focus on CAR-T treatments like Yescarta and Tecartus, Gilead aims to diversify into oncology. Anticipating a third of revenue from oncology by decade's end.

2 months ago·New York, United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.